Last reviewed · How we verify
IV insulin infusion
Insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Hyperglycemia in hospitalized patients, Diabetic ketoacidosis, Hyperglycemic hyperosmolar state.
At a glance
| Generic name | IV insulin infusion |
|---|---|
| Sponsor | Rush University Medical Center |
| Drug class | Insulin |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a peptide hormone that activates the insulin receptor, a transmembrane tyrosine kinase receptor. This triggers intracellular signaling cascades that increase glucose transport into muscle and adipose tissue, promote glycogen synthesis, and inhibit gluconeogenesis, thereby reducing hyperglycemia. IV infusion allows rapid onset and precise titration of blood glucose control in acute care settings.
Approved indications
- Hyperglycemia in hospitalized patients
- Diabetic ketoacidosis
- Hyperglycemic hyperosmolar state
Common side effects
- Hypoglycemia
- Hypokalemia
- Local injection site reactions
Key clinical trials
- Glycemic Targets During CPB in Elderly Diabetes (NA)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Prevention and Treatment of Common Hyperglycemia in Surgery Pilot (PHASE4)
- FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) (PHASE2)
- Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes (PHASE1, PHASE2)
- Automated Insulin for Management of Intrapartum Glycemia (NA)
- Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV insulin infusion CI brief — competitive landscape report
- IV insulin infusion updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI